Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients.
Matthew S SuskoChia-Ching Jackie WangAnn A LazarStephanie KimAngela LaffanMary FengAndrew KoAlan P VenookChloe E AtreyaKatherine Van LoonMekhail AnwarPublished in: The oncologist (2020)
Human immunodeficiency virus (HIV)-positive patients with anal squamous cell carcinoma can represent a difficult clinical scenario. Definitive radiation with concurrent chemotherapy is highly effective but can result in significant toxicity and a decrease in CD4 count that could predispose to HIV-related complications. As HIV-positive patients have largely been excluded from prospective clinical trials, this study seeks to provide greater understanding of their outcomes with radiation therapy, potential predictors of worse local control and overall survival, and those most at risk after completion of treatment.
Keyphrases
- hiv positive
- antiretroviral therapy
- human immunodeficiency virus
- men who have sex with men
- south africa
- hiv infected
- end stage renal disease
- locally advanced
- hiv testing
- squamous cell carcinoma
- radiation therapy
- hiv aids
- clinical trial
- ejection fraction
- hepatitis c virus
- newly diagnosed
- peritoneal dialysis
- chronic kidney disease
- prognostic factors
- randomized controlled trial
- type diabetes
- papillary thyroid
- risk factors
- weight loss
- lymph node metastasis
- patient reported
- drug induced
- squamous cell